An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.
An Tran-DuyMarjan Ghiti MoghadamMartijn A H Oude VoshaarHarald E VonkemanAnnelies BoonenPhilip ClarkeGeoff McCollPeter M Ten KloosterT R ZijlstraWillem F LemsN RiyaziE N GriepJ M W HazesRobert LandewéHein J Bernelot MoensPiet L C M van RielMart A F J van de LaarT L Jansennull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2018)
Although an official WTA is not defined, the mean saved cost of €368,269 per QALY lost seems acceptable in The Netherlands, given existing data on willingness to pay.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- open label
- rheumatoid arthritis patients
- study protocol
- ankylosing spondylitis
- phase iii
- clinical trial
- phase ii
- juvenile idiopathic arthritis
- interstitial lung disease
- randomized controlled trial
- health insurance
- big data
- machine learning
- radiation therapy
- combination therapy
- systemic sclerosis
- phase ii study
- artificial intelligence
- double blind